Analysis and characterization of the immune response after influenza, SARS-CoV-2 and pneumococcal vaccinations (IMMUNE Study)
Conditions
Interventions
Product Name: Covid-19 vaccine
Pharmaceutical Form: Dispersion for injection
Product Name: Influenza vaccine
Pharmaceutical Form: Suspension for injection
Product Name: Pneumococcal vaccine
Pharmace
Sponsors
Medizinische Universität Innsbruck
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Age (= 18 years) 2. Decision-making male and female Subjects 3. Has there been influenza, or SARS-CoV-2, or Pneumococcal vaccination (collective 1 + 2) or already fixed vaccination date with an influenza, or SARS-CoV-2, or pneumococcal vaccination (Collective 1) 4. Written, signed and dated Declaration of consent to participate in the clinical examination after prior written and oral explanation 5. Only applicable to subjects in collective 1: negative urine / serum pregnancy test Women of childbearing age Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 800 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 200
Exclusion criteria
Exclusion criteria: Exclusion criteria 1. The subject is a presence or Training service provider 2. Parallel vaccination with a second vaccine within ± 14 days 3. Participation in an interventional study in the active phase 4. Only applicable to subjects in collective 1: Breastfeeding period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The aim of the study is the immune response (Antibody titre, B- and T-cell immunity) of different Patient groups and healthy volunteers after Influenza, SARS-CoV-2 and pneumococcal vaccinations too examine. ;Secondary Objective: Primary endpoint: immune response (antibody titre, B and T cell immunity) Secondary endpoint: association between immunological and laboratory parameters and the Immune response ;Primary end point(s): Association between immunological and laboratory parameters and the Immune response. ;Timepoint(s) of evaluation of this end point: - | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): -;Timepoint(s) of evaluation of this end point: - | — |
Countries
Austria
Contacts
Public ContactSponsor and PI
Medizinische Universität Innsbruck
Outcome results
None listed